Proteome Sciences Announces £5M Placing
News Feb 24, 2014
Proteome Sciences plc announces that it has conditionally placed 17,857,143 new ordinary shares of 1p each to raise £5 million before expenses with new and existing investors at 28p per share to provide additional working capital for the Company. Christopher Pearce, Chief Executive of the Proteome Sciences, has subscribed for 3,571,429 New Ordinary Shares in the Placing at the Placing Price. Following this transaction Christopher Pearce will hold 35,109,504 ordinary shares in the Company representing 16.4 per cent. of the Company’s enlarged share capital.
Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that dealings in the New Ordinary Shares will commence trading at 08:00 on or around 28 February 2014. Following Admission, The New Ordinary Shares will, when issued, rank pari passu in all respects with the existing ordinary shares.
In conformity with rule 5.6.1 of Disclosure and Transparency Rules, the Board of the Company notifies the market of the following:
The total number of ordinary shares of 1p each in Proteome in issue following the admission of the 17,857,143 New Ordinary Shares will be 214,105,620 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Proteome Sciences under the FCA's Disclosure and Transparency Rules.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE